{"title":"The causal relationship between 233 metabolites and coronary atherosclerosis: a Mendelian randomization study.","authors":"Hongwei Zhang, Xiaoyu Zheng, Zian Yan, Lijun Guo, Yuan Zheng, Dawu Zhang, Xiaochang Ma","doi":"10.3389/fcvm.2024.1439699","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the causal relationship between 233 newly reported metabolites and coronary atherosclerosis through Mendelian randomization analysis.</p><p><strong>Methods: </strong>Five different methods were used to perform Mendelian randomization analysis on the 233 metabolites and coronary atherosclerosis, with inverse variance weighting as the primary result, supplemented by other methods.</p><p><strong>Results: </strong>The analysis identified that certain metabolites increase the susceptibility risk of coronary atherosclerosis, including: Total fatty acids (OR = 1.40, 95% CI: 1.28-1.53, <i>P</i> < 0.001), Saturated fatty acids (OR = 1.44, 95% CI: 1.30-1.60, <i>P</i> < 0.001), Serum total triglyceride levels (OR = 1.33, 95% CI: 1.22-1.46, <i>P</i> < 0.001), Conjugated linoleic acid (OR = 1.16, 95% CI: 1.04-1.30, <i>P</i> = 0.007). Conversely, certain metabolites were found to reduce the occurrence of coronary atherosclerosis, such as: Cholesteryl esters to total lipids ratio in medium HDL (OR = 0.73, 95% CI: 0.67-0.78, <i>P</i> < 0.001), Cholesteryl esters to total lipids ratio in large HDL (OR = 0.64, 95% CI: 0.58-0.71, <i>P</i> < 0.001), Total cholesterol to total lipids ratio in medium HDL (OR = 0.71, 95% CI: 0.65-0.77, <i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>There is a close relationship between metabolites and the occurrence of coronary atherosclerosis. This study conducted Mendelian randomization analysis on the causal relationship between 233 metabolites and coronary atherosclerosis, providing potential new insights for the treatment of this disease.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1439699"},"PeriodicalIF":2.8000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669696/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2024.1439699","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To investigate the causal relationship between 233 newly reported metabolites and coronary atherosclerosis through Mendelian randomization analysis.
Methods: Five different methods were used to perform Mendelian randomization analysis on the 233 metabolites and coronary atherosclerosis, with inverse variance weighting as the primary result, supplemented by other methods.
Results: The analysis identified that certain metabolites increase the susceptibility risk of coronary atherosclerosis, including: Total fatty acids (OR = 1.40, 95% CI: 1.28-1.53, P < 0.001), Saturated fatty acids (OR = 1.44, 95% CI: 1.30-1.60, P < 0.001), Serum total triglyceride levels (OR = 1.33, 95% CI: 1.22-1.46, P < 0.001), Conjugated linoleic acid (OR = 1.16, 95% CI: 1.04-1.30, P = 0.007). Conversely, certain metabolites were found to reduce the occurrence of coronary atherosclerosis, such as: Cholesteryl esters to total lipids ratio in medium HDL (OR = 0.73, 95% CI: 0.67-0.78, P < 0.001), Cholesteryl esters to total lipids ratio in large HDL (OR = 0.64, 95% CI: 0.58-0.71, P < 0.001), Total cholesterol to total lipids ratio in medium HDL (OR = 0.71, 95% CI: 0.65-0.77, P < 0.001).
Conclusion: There is a close relationship between metabolites and the occurrence of coronary atherosclerosis. This study conducted Mendelian randomization analysis on the causal relationship between 233 metabolites and coronary atherosclerosis, providing potential new insights for the treatment of this disease.
期刊介绍:
Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers?
At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.